Neucyte Inc., a minority-owned small business, has been awarded a $500,000 Project Grant from the National Institute on Aging (CFDA 93.866 - Aging Research) to develop a nanoluciferase-based microphysiological systems (MPS) platform for high-throughput screening of Alzheimer's disease (AD) and AD-related dementia (ADRD) therapeutics. The project aims to create a scalable, reproducible "mini-brain" assembled organoid model using patient-derived induced pluripotent stem cells to better recapitulate the in vivo environment for preclinical drug discovery. The proposed MPS platform will incorporate bioluminescence-based assays to enable effective and high-throughput screening of potential AD/ADRD treatments, addressing challenges in translating discoveries from animal models to human brain-specific diseases. The successful completion of the Phase I effort will establish the feasibility for commercializing this advanced AD/ADRD drug screening platform.
Generated 2/25/25, 4:52 AM